Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Trial Profile

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 09 May 2018

At a glance

  • Drugs Lapatinib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 02 May 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
    • 06 Jun 2017 Results (n=23) comparing transcriptome and kinome profiles before and after treatment with FDA-approved anti-HER2 drugs and combinations, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top